Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) FCF Margin: 2018-2025

Historic FCF Margin for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to 19,954.55%.

  • Cidara Therapeutics' FCF Margin rose 2063975.00% to 19,954.55% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,564.98%, marking a year-over-year decrease of 148795.00%. This contributed to the annual value of -13,855.84% for FY2024, which is 1375733.00% down from last year.
  • As of Q1 2025, Cidara Therapeutics' FCF Margin stood at 19,954.55%, which was up 158.02% from -34,391.72% recorded in Q2 2024.
  • Over the past 5 years, Cidara Therapeutics' FCF Margin peaked at 19,954.55% during Q1 2025, and registered a low of -34,391.72% during Q2 2024.
  • Moreover, its 3-year median value for FCF Margin was -54.96% (2023), whereas its average is -2,180.77%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by 3,444,506bps in 2024, then skyrocketed by 2,063,975bps in 2025.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' FCF Margin stood at -533.71% in 2021, then soared by 32,811bps to -205.61% in 2022, then soared by 8,939bps to -116.22% in 2023, then slumped by 3,444,506bps to -34,391.72% in 2024, then surged by 2,063,975bps to 19,954.55% in 2025.
  • Its FCF Margin was 19,954.55% in Q1 2025, compared to -34,391.72% in Q2 2024 and -685.20% in Q1 2024.